In a nutshell The authors aimed to determine whether palbociclib (Ibrance) could help treat women hormone-receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) metastatic (cancer has spread) breast cancer. The addition of palbociclib showed consistent success against breast cancer that had become resistant...
Read More
In a nutshell This study examined the effect of the drug combination, palbociclib (Ibrance) plus fulvestrant (Faslodex) on the quality of life of breast cancer patients. The study concluded that palbociclib plus fulvestrant allowed patients to maintain a good quality of life while experiencing delayed disease progression. Some background...
Read More
In a nutshell This study investigated the impact of metabolic syndrome on treatment outcome with abiraterone acetate (Zytiga) for hormone-resistant prostate cancer. Researchers concluded that metabolic syndrome has an adverse outcome on disease progression in advanced prostate cancer. Some background Hormone therapy is a common treatment used in...
Read More
In a nutshell This study examined the effects of enzalutamide (Xtandi) in improving disease-related symptoms associated with advanced metastatic prostate cancer. The researchers concluded that enzalutamide treatment is effective in managing prostate cancer-derived bone tumors and pain among men with advanced prostate cancer. Some background When...
Read MoreIn a nutshell This review evaluated newly approved treatments for metastatic castration-resistant prostate cancer. Researchers concluded that a number of recently developed treatments provide a clinical benefit for men with metastatic castration-resistant prostate cancer. Some background Treatment for metastatic (cancer that has spread to...
Read More
In a nutshell This study examined the effects of enzalutamide (Xtandi) with respect to the site of metastatic castration-resistant prostate cancer. Researchers concluded that enzalutamide is a safe and effective treatment for all sites of metastases studied. Some background When prostate cancer spreads outside of the prostate (also called...
Read MoreIn a nutshell This study aimed to assess the efficacy and safety of anti-cancer drug trametinib (Mekinist) in comparison to docetaxel (Taxotere) in treating patients with KRAS-mutation-positive advanced non-small-cell lung cancer (NSCLC). The study concluded that there was no difference in efficacy between trametinib and docetaxel however trametinib...
Read MoreIn a nutshell This phase II trial aims to evaluate the effectiveness of a personalized peptide-based vaccine (Multi-Epitope TARP) on preventing progression of localized prostate cancer. The main outcome to be investigated is disease progression based on blood tests. The trial is recruiting in Maryland (USA). The details Immunotherapy has recently...
Read More
In a nutshell The authors aimed to determine if palbociclib (Ibrance) could help treat women with metastatic (spread to other areas of the body) breast cancer. The researchers concluded that palbociclib showed good response rates from women with metastatic breast cancer whose cells expressed a protein called retinoblastoma (Rb). Some background...
Read More
In a nutshell This review aimed to assess the efficacy and safety of the new anticancer drug dacomitinib in comparison to current drug erlotinib. Both drugs are used to treat advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. The study found that dacomitinib was marginally more effective than erlotinib in specific EGFR-mutant-NSCLC. Some...
Read More
In a nutshell This study examined abiraterone acetate (Zytiga) as a treatment option for older men with metastatic castration-resistant prostate cancer. Researchers concluded that abiraterone acetate improves overall survival in younger as well as older men with metastatic castration resistant prostate cancer. Some background...
Read More
In a nutshell This study investigated the treatment of progressive therapy-resistant colorectal cancer with panitumumab (Vectibix). It was found that panitumumab was a safe and effective treatment for CRC patients who had progressed despite treatment. Some background Chemotherapy is generally the first treatment option for colorectal...
Read More
